Donald F. Weaver
Oprichter bij Treventis Corp.
Actieve functies van Donald F. Weaver
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Oprichter | 07-04-2010 | - |
Hoofd Techniek/Wetenschap/O&O | - | - | |
Voorzitter | - | - | |
Dalhousie University | Corporate Officer/Principal | - | - |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Hoofd Techniek/Wetenschap/O&O | 22-03-2013 | - |
Oprichter | 01-01-2006 | - | |
Corporate Officer/Principal | 01-01-2006 | 22-03-2013 | |
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Oprichter | - | - |
Loopbaan van Donald F. Weaver
Eerdere bekende functies van Donald F. Weaver
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Molecular Mining Corp. | Oprichter | 22-03-2013 | 22-03-2013 |
Corporate Officer/Principal | - | 22-03-2013 | |
Canada Research Chairs Program | Corporate Officer/Principal | - | - |
Statistieken
Internationaal
Canada | 6 |
Zwitserland | 2 |
Operationeel
Founder | 4 |
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | Commercial Services |
Treventis Corp.
Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada. | Health Technology |
Canada Research Chairs Program | Government |
Molecular Mining Corp. | |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | Health Technology |
- Beurs
- Insiders
- Donald F. Weaver
- Ervaring